Candel Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 12, 2026, covering the fiscal quarter ended September 30, 2026.
Key Highlights
- Share count: As of November 5, 2026, Candel Therapeutics had 78,445,937 shares of common stock, $0.01 par value per share, outstanding.
- No product revenue: According to the filing, the company has not generated any revenue from product sales and expects to continue incurring significant expenses and increasing operating losses.
- Filer classification: The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company under the Exchange Act.
- Key pipeline candidates: The filing identifies aglatimagene besadenovec and linoserpaturev as the company's principal product candidates, both still in clinical development.
- Funding risk disclosed: The company stated it will need to raise substantial additional funding or would be forced to delay, reduce, or eliminate product development programs or initiate steps to cease operations.
- RTW Purchase Agreement: The filing discloses that the terms of the RTW Purchase Agreement currently impose restrictions on the company's operating and financial flexibility.
Candel Therapeutics Q3 2026: Pipeline, Funding, and Operating Status
Candel Therapeutics, Inc. (NASDAQ:CADL), a clinical-stage biopharmaceutical company headquartered at 117 Kendrick St, Suite 450, Needham, MA 02494, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing carries Commission File Number 001-40829 and was submitted on November 12, 2026. The company's common stock is listed on The Nasdaq Global Market under the ticker symbol CADL.
According to the filing, Candel Therapeutics has not generated any revenue from product sales and "expect[s] to continue to incur significant expenses and increasing operating losses for the foreseeable future." The company disclosed that it will require substantial additional capital to continue development activities, warning that an inability to raise funds "would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts or initiate steps to cease operations." The filing also noted the company has incurred indebtedness and may incur additional indebtedness, which the registrant acknowledged "could adversely affect our financial condition."
The company's two named lead product candidates are aglatimagene besadenovec (referred to in the filing as "aglatimagene") and linoserpaturev. Both require additional clinical development before the company may seek regulatory approval, according to the filing. The registrant also disclosed a license agreement with Mass General Brigham (MGB) as a component of its business operations. The filing contains forward-looking statements, which the company characterized as subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements.
What Was Disclosed
Candel Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 78,445,937 shares outstanding as of November 5, 2026, continued pre-revenue status, two clinical-stage pipeline candidates, and risks related to funding and existing indebtedness under the RTW Purchase Agreement.




Please wait processing your request...